MX2017005243A - Reducción de la viscosidad de formulaciones farmacéuticas. - Google Patents

Reducción de la viscosidad de formulaciones farmacéuticas.

Info

Publication number
MX2017005243A
MX2017005243A MX2017005243A MX2017005243A MX2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
reducing viscosity
acetyl
viscosity
pharmaceutical formulation
Prior art date
Application number
MX2017005243A
Other languages
English (en)
Other versions
MX388858B (es
Inventor
James Sloey Christopher
KANAPURAM Sekhar
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005243(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017005243A publication Critical patent/MX2017005243A/es
Publication of MX388858B publication Critical patent/MX388858B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método para reducir la viscosidad de una formulación farmacéutica que utiliza una concentración de reducción de la viscosidad de un excipiente seleccionado del grupo que consiste de la n-acetil arginina, n-acetil lisina, n-acetil prolina y mezclas de los mismos en combinación con una proteína terapéutica. También se proporciona una formulación farmacéutica estable.
MX2017005243A 2014-10-23 2015-10-22 Reducción de la viscosidad de formulaciones farmacéuticas MX388858B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23
PCT/US2015/056972 WO2016065181A1 (en) 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations

Publications (2)

Publication Number Publication Date
MX2017005243A true MX2017005243A (es) 2017-08-18
MX388858B MX388858B (es) 2025-03-20

Family

ID=54427875

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005243A MX388858B (es) 2014-10-23 2015-10-22 Reducción de la viscosidad de formulaciones farmacéuticas
MX2021015789A MX2021015789A (es) 2014-10-23 2017-04-21 Reduccion de la viscosidad de formulaciones farmaceuticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015789A MX2021015789A (es) 2014-10-23 2017-04-21 Reduccion de la viscosidad de formulaciones farmaceuticas.

Country Status (17)

Country Link
US (3) US11813328B2 (es)
EP (2) EP3909611B1 (es)
JP (3) JP2017531682A (es)
KR (1) KR102534017B1 (es)
CN (2) CN107206070B (es)
AU (2) AU2015335743B2 (es)
BR (1) BR112017008125B1 (es)
CA (1) CA2964786C (es)
CL (2) CL2017000984A1 (es)
EA (3) EA038462B1 (es)
ES (1) ES2964713T3 (es)
IL (2) IL287947B2 (es)
MA (1) MA54716A (es)
MX (2) MX388858B (es)
SG (1) SG11201703152RA (es)
WO (1) WO2016065181A1 (es)
ZA (1) ZA201702762B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP3522918A1 (en) 2016-10-06 2019-08-14 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
MA48461A (fr) 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
MA48464A (fr) * 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
WO2020008022A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
US12599669B2 (en) 2019-04-23 2026-04-14 Amgen Inc. Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
EP4103235A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Formulations of human anti-tslp antibodies and methods of treating inflammatory disease
KR102746418B1 (ko) * 2020-12-03 2024-12-26 동국대학교 산학협력단 N-아세틸-l-아르기닌을 포함하는 단백질 응집 억제용 조성물
WO2022191550A1 (ko) * 2021-03-09 2022-09-15 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
EP4319795A4 (en) * 2021-04-09 2025-03-05 Avantor Performance Materials, LLC Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations
WO2025175164A1 (en) * 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
WO1999024063A1 (en) 1997-11-07 1999-05-20 Chiron Corporation Compositions providing for increased igf-i solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
MXPA02009485A (es) * 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
AU3070702A (en) 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CA2512174A1 (en) 2003-01-30 2004-08-12 Christian B. Allan Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
JP2010530233A (ja) 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
KR101614983B1 (ko) * 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제
DK2531218T3 (en) * 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
BR112012021576A2 (pt) * 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
ES2825704T3 (es) 2014-12-03 2021-05-17 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
SG10201912565QA (en) 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
EP3522918A1 (en) 2016-10-06 2019-08-14 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
CN107206070B (zh) 2022-01-18
CA2964786C (en) 2023-10-17
KR20170071518A (ko) 2017-06-23
EP3209332A1 (en) 2017-08-30
WO2016065181A1 (en) 2016-04-28
BR112017008125A2 (pt) 2018-06-19
CN107206070A (zh) 2017-09-26
EA033444B1 (ru) 2019-10-31
JP2017531682A (ja) 2017-10-26
EA201790787A1 (ru) 2017-08-31
IL251726A0 (en) 2017-06-29
US20250345421A1 (en) 2025-11-13
JP2020037559A (ja) 2020-03-12
AU2015335743B2 (en) 2020-12-24
EP3909611A1 (en) 2021-11-17
CA2964786A1 (en) 2016-04-28
MX2021015789A (es) 2022-01-27
US20240066124A1 (en) 2024-02-29
ZA201702762B (en) 2022-12-21
SG11201703152RA (en) 2017-05-30
US11813328B2 (en) 2023-11-14
CN114569716A (zh) 2022-06-03
CL2019002190A1 (es) 2019-11-22
MA54716A (fr) 2021-11-17
AU2021200990B2 (en) 2023-02-16
IL287947B1 (en) 2024-04-01
CL2017000984A1 (es) 2018-01-05
JP7411615B2 (ja) 2024-01-11
JP2022009223A (ja) 2022-01-14
AU2015335743A1 (en) 2017-05-04
ES2964713T3 (es) 2024-04-09
IL287947A (en) 2022-01-01
MX388858B (es) 2025-03-20
US12318447B2 (en) 2025-06-03
EP3909611B1 (en) 2023-08-30
BR112017008125B1 (pt) 2023-11-21
EA201991447A1 (ru) 2019-11-29
AU2021200990A1 (en) 2021-03-11
KR102534017B1 (ko) 2023-05-19
IL287947B2 (en) 2024-08-01
JP6965321B2 (ja) 2021-11-10
US20170333559A1 (en) 2017-11-23
EA038462B1 (ru) 2021-08-31
EP3209332B1 (en) 2021-05-26
EA202191513A1 (ru) 2021-11-30
IL251726B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX2017005243A (es) Reducción de la viscosidad de formulaciones farmacéuticas.
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201592106A2 (ru) Локальное сопутствующее введение толерогенных синтетических наноносителей для снижения гиперчувствительности типа i и гиперчувствительности типа iv
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
AR092219A1 (es) Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
CL2015002897A1 (es) Inhibidores de bace1
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.